The Filing Desk

OPKO Health

OPK · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

OPK · Last close · November 13, 2026
$1.68
Value OPKO Health yourself

OPKO Health's revenue fell 14.9% to $607 million in fiscal 2025. Its operating margin was −19.4%, up from −21.3% a year earlier. Free cash flow was −$191 million. It paid out $47 million in dividends and buybacks. The diluted share count rose 8.2%.

OPKO Health, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076596 Updated
Revenue
$607M
14.9%
Operating margin
−19.4%
2.0 pts
Net income
−$226M
 
Free cash flow
−$191M
 
Return on capital
−7.0%
1.9 pts
Market cap
$1.3B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

What OPKO Health does

OPKO Health, based in Miami, is a healthcare company with two segments: pharmaceuticals and diagnostics. Its drug business includes NGENLA, a once-weekly growth hormone injection for children with growth problems, which it developed and which Pfizer develops further and sells. NGENLA has approvals in more than 50 markets. OPKO also makes and sells Rayaldee, a treatment for a parathyroid problem in adults with chronic kidney disease.

It runs drug businesses in Spain, Ireland, Chile and Mexico. Its Irish unit, EirGen, makes high-potency pills and exports them to over 60 countries. Its subsidiary ModeX is developing early-stage drugs that combine several antibody parts into one molecule, to treat cancer and infectious diseases. ModeX is working with Merck and Regeneron.

Its diagnostics business is BioReference Health, a clinical laboratory. In 2024 and 2025 OPKO sold several parts of it, including its oncology testing and most of its clinical and women's health businesses outside New York and New Jersey, for total consideration of up to $462.5 million. BioReference now focuses on routine and women's health testing in New York and New Jersey and on specialty urology tests, including the 4Kscore prostate cancer test. OPKO has had operating losses in the past.

Its biggest risks, as it describes them

  • A history of operating losses and uncertainty about reaching profitability soon.
  • Research that may not lead to commercially viable products or regulatory approvals.
  • Failing to bill and collect properly for its laboratory services.
  • Depending on its chairman and chief executive, and on partners such as Pfizer.
  • Risks of doing business in many countries, and of acquisitions and funding for them.
From OPKO Health's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

OPKO Health lost money in fiscal 2025: a net loss of $226 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments13515396427364
Debt incl. finance leases21026610443349
Net debt (negative means net cash)76113−8616−15
Net debt to EBITDA0.8x————
Debt to equity0.1x0.2x0.0x0.3x0.3x
Interest coverage1.0x−18.8x−11.6x−3.2x—
Current ratio2.5x1.9x1.6x3.4x4.0x
Quick ratio2.2x1.5x1.2x3.1x3.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project OPKO Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of OPKO Health reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 93 of 94 of 9
Rule of 40−19.2%−46.6%−46.3%
Altman Z''−1.08−0.41−0.79
Accruals ratio−7.7%6.2%−2.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assetsPassFailPass
Current ratio roseFailPassPass
Share count didn't riseFailPassFail
Gross margin rosePassFailPass
Revenue rose relative to assetsFailFailFail
F-score4 of 93 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put OPKO Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
OPKO HealthFY25−14.9%−19.4%−31.4%−7.0%—4
Ultragenyx PharmaceuticalFY2520.2%−79.5%−70.1%———Compare
Kiniksa PharmaceuticalsFY2560.1%11.4%20.1%———Compare
Mirum PharmaceuticalsFY2554.7%−4.2%10.5%−7.1%−34.9x5Compare
Amphstar PharmaceuticalsFY25−1.6%19.5%16.8%9.9%1.7x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1,1189669909021,4351,7751,004864713607
Revenue growth127.2%−13.6%2.5%−8.9%59.1%23.6%−43.4%−14.0%−17.4%−14.9%
Gross profit553905————288318218206
Research and development11412612611875777490105124
Operating income−97−276−171−2745819−226−157−152−117
Net income−48−305−153−31531−30−328−189−53−226
Diluted EPS (US$)−0.10−0.55−0.27−0.530.05−0.05−0.46−0.25−0.08−0.30
Diluted shares (millions)556559563596641648719752694751
Cash flow
Cash from operations32−92−109−1724038−95−28−184−178
Capital expenditure18462813343225162512
Free cash flow14−139−137−18566−120−44−208−191
Dividends paid0000000000
Share buybacks000000009047
Acquisitions16000042000
Stock-based compensation4328221391418111111
Balance sheet at fiscal year end
Cash and short-term investments1699296867213515396427364
Debt incl. finance leases13141027725621026610443349
Total assets2,7672,5902,4512,3092,4732,4002,1672,0122,2001,932
Total liabilities675746660694802715606622835664
Shareholders' equity2,0461,8441,7911,6151,6721,6851,5621,3891,3651,268
Margins and ratios
Gross margin49.5%93.7%————28.7%36.8%30.6%33.9%
Operating margin−8.6%−28.6%−17.3%−30.4%4.0%1.1%−22.5%−18.2%−21.3%−19.4%
Net margin−4.3%−31.6%−15.4%−34.9%2.1%−1.7%−32.7%−21.9%−7.5%−37.2%
Free cash flow margin1.2%−14.3%−13.8%−20.5%0.4%0.3%−11.9%−5.2%−29.2%−31.4%
Rule of 40 (growth + FCF margin)128.5%−27.9%−11.3%−29.5%59.5%24.0%−55.3%−19.2%−46.6%−46.3%
Return on capital−4.2%−11.9%−7.8%−12.3%2.0%0.8%−10.4%−8.3%−8.9%−7.0%
Return on equity−2.4%−15.7%−8.4%−18.5%1.9%−1.8%−20.2%−12.8%−3.9%−17.1%
Return on assets−1.7%−11.4%−6.1%−13.2%1.3%−1.2%−14.4%−9.0%−2.5%−10.9%
Net debt to EBITDA−6,241.4x———1.3x0.8x————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: OPKO Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with OPKO Health.